Labcorp Holdings Inc. (LH)
Labcorp Holdings Inc. (LH) Interest Expense
The interest expense for Labcorp Holdings Inc. (LH) is $224.10 Million with a year-over-year change of +7.59%. Interest expense is the cost a company incurs for borrowed funds, including interest on bonds, loans, and other forms of debt financing.
LH Interest Expense Chart
LH Interest Expense
$224.10M
Zoom
Current Interest Expense
$224.10M
$224.10 Million
Year-over-Year Change
+7.59%
vs. $208.30M prior year
Historical Data
30
Years of data available
Annual Interest Expense History
| Year | Interest Expense | YoY Change | % Change |
|---|---|---|---|
| 2025 | $224.10M | +$15.80M | +7.59% |
| 2024 | $208.30M | +$8.70M | +4.36% |
| 2023 | $199.60M | +$19.80M | +11.01% |
| 2022 | $179.80M | $-32.00M | -15.11% |
| 2021 | $211.80M | +$4.40M | +2.12% |
| 2020 | $207.40M | $-33.30M | -13.83% |
| 2019 | $240.70M | $-3.50M | -1.43% |
| 2018 | $244.20M | +$9.10M | +3.87% |
| 2017 | $235.10M | +$16.00M | +7.30% |
| 2016 | $219.10M | $-55.80M | -20.30% |
| 2015 | $274.90M | +$165.40M | +151.05% |
| 2014 | $109.50M | +$13.00M | +13.47% |
| 2013 | $96.50M | +$2.00M | +2.12% |
| 2012 | $94.50M | +$7.00M | +8.00% |
| 2011 | $87.50M | +$17.50M | +25.00% |
| 2010 | $70.00M | +$7.10M | +11.29% |
| 2009 | $62.90M | $-9.10M | -12.64% |
| 2008 | $72.00M | +$72.00M | — |
| 2007 | $0 | +$0 | — |
| 2006 | $0 | +$0 | — |
| 2005 | $0 | +$0 | — |
| 2004 | $0 | +$0 | — |
| 2003 | $0 | +$0 | — |
| 2002 | $0 | +$0 | — |
| 2001 | $0 | +$0 | — |
| 2000 | $0 | +$0 | — |
| 1999 | $0 | +$0 | — |
| 1998 | $0 | +$0 | — |
| 1997 | $0 | +$0 | — |
| 1996 | $0 | — | — |
Data as of Sunday, June 14, 2026
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter